Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Boehringer Ingelheim
Merck
Moodys
Mallinckrodt

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,911,461

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,911,461
Title: 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
Abstract:The invention concerns 2-oxo-1-pyrrolidine derivatives of formula I, ##STR1## wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention are particularly suited for treating neurological disorders such as epilepsy.
Inventor(s): Differding; Edmond (Louvain-la Neuve, BE), Kenda; Benoit (Emines, BE), Lallemand; Benedicte (Waimes, BE), Matagne; Alain (Gerpinnes, BE), Michel; Philippe (Beersel, BE), Pasau; Patrick (Chastre, BE), Talaga; Patrice (Watermael-Boitsfort, BE)
Assignee: UCB, S.A. (Brussels, BE)
Application Number:10/693,917
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,911,461

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ucb Inc BRIVIACT brivaracetam SOLUTION;INTRAVENOUS 205837-001 May 12, 2016 RX Yes Yes   Start Trial   Start Trial Y Y TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY   Start Trial
Ucb Inc BRIVIACT brivaracetam SOLUTION;INTRAVENOUS 205837-001 May 12, 2016 RX Yes Yes   Start Trial   Start Trial Y Y TREATMENT OF PARTIAL ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY   Start Trial
Ucb Inc BRIVIACT brivaracetam SOLUTION;ORAL 205838-001 May 12, 2016 RX Yes Yes   Start Trial   Start Trial Y Y TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER   Start Trial
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-001 May 12, 2016 RX Yes No   Start Trial   Start Trial Y Y TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER   Start Trial
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-002 May 12, 2016 RX Yes No   Start Trial   Start Trial Y Y TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER   Start Trial
Ucb Inc BRIVIACT brivaracetam TABLET;ORAL 205836-003 May 12, 2016 RX Yes No   Start Trial   Start Trial Y Y TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,911,461

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0004297Feb 23, 2000

International Family Members for US Patent 6,911,461

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 282592   Start Trial
Austria 304999   Start Trial
Austria 325093   Start Trial
Austria 445597   Start Trial
Austria 488500   Start Trial
Australia 2001252144   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Mallinckrodt
Merck
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.